AAV Vector GLA Expression for Fabry Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Fabry disease are ineffective due to the development of neutralizing antibodies and require lifelong intravenous administration, failing to provide a cure for the progressive kidney and cardiac complications associated with the deficiency of α-galactosidase A (GLA).
Innovation Solution
Development of optimized cassettes for liver-directed expression of a secretable version of human α-galactosidase A (GLA) that increase GLA secretion, enabling hepatic gene transfer to achieve systemic correction of GLA deficiency, using polynucleotides with specific sequence identities and introns, and adeno-associated virus (AAV) vectors for targeted gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is administered to treat Fabry disease, then the deficiency of α-galactosidase A is temporarily compensated, but patients develop neutralizing antibodies that render the therapy ineffective and require lifelong weekly intravenous administration
Solution Approach 1:
The patent applies preliminary action by using AAV vectors to deliver the GLA gene to hepatocytes before the disease progresses severely, establishing endogenous enzyme production that provides long-term therapeutic effect without requiring repeated administrations. The gene transfer is performed once, and the liver cells continuously produce functional α-galactosidase A enzyme
Solution Approach 2:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver the therapeutic GLA gene to liver cells. The AAV vector acts as a mediator that transfers the genetic material into hepatocytes, enabling them to produce functional enzyme without direct repeated administration of the enzyme itself, thereby avoiding antibody formation
2Reliability
If optimized cassettes with specific sequence identities are used for liver-directed expression, then GLA secretion is increased to achieve systemic correction, but the complexity of the expression cassette design increases
Solution Approach 1:
The patent applies parameter changes by optimizing specific parameters of the expression cassette including nucleotide sequence identity (at least 75%, 80%, 85%, 90%, 95%, or 99% identity to reference sequences), codon optimization for hepatic expression, and selection of specific promoter and enhancer elements. These parameter optimizations enhance GLA secretion efficiency from liver cells while maintaining manageable design complexity through systematic optimization approaches
Data Source
AI summary
Polynucleotides including nucleic acids encoding α-galactosidase A (GLA) are described. Also described are expression cassettes, vectors, cells, and cell lines containing the polynucleotides, as well as methods of using the polynucleotides to treat lysosomal storage disorders such as Fabry disease.